Esperion Therapeutics, Inc. $ESPR Shares Bought by Parallel Advisors LLC

Key Points

• Parallel Advisors LLC dramatically increased its holdings in Esperion Therapeutics by 1,174.2% in the second quarter, acquiring an additional 117,424 shares to own a total of 127,424 shares valued at $125,000.
• Multiple institutions, including Bank of America Corp DE and Nuveen Asset Management LLC, significantly boosted their stakes in Esperion Therapeutics during the fourth quarter, indicating strong institutional interest.
• Esperion Therapeutics' current stock price is $2.48, with recent reports highlighting a negative EPS but positive revenue performance, exceeding analyst estimates.

Parallel Advisors LLC increased its position in Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 1,174.2% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 127,424 shares of the biopharmaceutical company's stock after purchasing an additional 117,424 shares during the period. Parallel Advisors LLC owned 0.06% of Esperion Therapeutics worth $125,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. BNP Paribas Financial Markets boosted its stake in Esperion Therapeutics by 24.2% in the fourth quarter. BNP Paribas Financial Markets now owns 153,212 shares of the biopharmaceutical company's stock valued at $337,000 after acquiring an additional 29,879 shares during the period. Bank of America Corp DE boosted its stake in Esperion Therapeutics by 45.1% in the fourth quarter. Bank of America Corp DE now owns 1,629,980 shares of the biopharmaceutical company's stock valued at $3,586,000 after acquiring an additional 506,428 shares during the period. Nuveen Asset Management LLC boosted its stake in Esperion Therapeutics by 48.6% in the fourth quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company's stock valued at $6,862,000 after acquiring an additional 1,020,243 shares during the period. ProShare Advisors LLC raised its holdings in shares of Esperion Therapeutics by 75.2% during the fourth quarter. ProShare Advisors LLC now owns 62,549 shares of the biopharmaceutical company's stock valued at $138,000 after buying an additional 26,843 shares during the last quarter. Finally, Mackenzie Financial Corp raised its holdings in shares of Esperion Therapeutics by 116.1% during the fourth quarter. Mackenzie Financial Corp now owns 143,252 shares of the biopharmaceutical company's stock valued at $315,000 after buying an additional 76,965 shares during the last quarter. 47.39% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on ESPR shares. HC Wainwright reaffirmed a "buy" rating and set a $16.00 price target on shares of Esperion Therapeutics in a report on Friday, September 19th. Wall Street Zen cut Esperion Therapeutics from a "buy" rating to a "hold" rating in a report on Monday, August 25th. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $7.00.

Esperion Therapeutics Stock Down 1.2%

Shares of Esperion Therapeutics stock opened at $2.48 on Wednesday. The stock has a market cap of $500.02 million, a PE ratio of -5.06, a price-to-earnings-growth ratio of 56.38 and a beta of 0.89. Esperion Therapeutics, Inc. has a 12 month low of $0.69 and a 12 month high of $3.94. The business has a fifty day simple moving average of $2.03 and a 200-day simple moving average of $1.43.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.15. Esperion Therapeutics had a negative return on equity of 0.91% and a negative net margin of 35.84%.The business had revenue of $82.39 million during the quarter, compared to analyst estimates of $62.55 million. Analysts expect that Esperion Therapeutics, Inc. will post -0.29 EPS for the current fiscal year.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.